Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Drop in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 15,389 shares, a decrease of 75.8% from the February 12th total of 63,474 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 26,215 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 26,215 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.0% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of brokerages recently commented on NBTX. Guggenheim raised their price target on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Nanobiotix Trading Down 4.3%

Shares of NBTX traded down $1.44 during mid-day trading on Thursday, reaching $31.80. The company had a trading volume of 22,650 shares, compared to its average volume of 38,709. The company’s 50 day simple moving average is $24.79 and its 200 day simple moving average is $20.85. Nanobiotix has a 1-year low of $2.99 and a 1-year high of $41.89.

Institutional Trading of Nanobiotix

A number of hedge funds and other institutional investors have recently modified their holdings of NBTX. Millennium Management LLC acquired a new position in shares of Nanobiotix during the fourth quarter worth $390,000. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Marshall Wace LLP bought a new stake in Nanobiotix during the 4th quarter worth $220,000. Finally, Optiver Holding B.V. bought a new stake in Nanobiotix during the 3rd quarter worth $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.